NCT00086736View on ClinicalTrials.gov

Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2001

Primary Completion Date

November 30, 2003

Study Completion Date

November 30, 2003

Conditions

Prostate Cancer

Interventions

DRUG

bicalutamide

DRUG

eflornithine

DRUG

oral eflornithine placebo

DRUG

oral bicalutamide placebo

Trial Locations (1)

35294-3300

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Alabama at Birmingham

OTHER

NCT00086736 - Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy | Biotech Hunter | Biotech Hunter